{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:18:46Z","timestamp":1787505526402,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40272-025-00722-5","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:10:59Z","timestamp":1759144259000},"page":"771-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fremanezumab: Pediatric First Approval"],"prefix":"10.1007","volume":"27","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"722_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067670","author":"A Hovaguimian","year":"2022","unstructured":"Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022. https:\/\/doi.org\/10.1136\/bmj-2021-067670.","journal-title":"BMJ"},{"key":"722_CR2","unstructured":"Teva Pharmaceutical Industries Ltd. Teva announces U.S. approval of AJOVY\u2122 (fremanezumab-vfrm) injection, the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults [media release]. 14 Sep 2018. http:\/\/www.tevapharm.com."},{"key":"722_CR3","unstructured":"Teva Pharmaceutical Industries Ltd. Teva's AJOVY\u00ae receives EU approval offering patients the first and only anti-CGRP treatment with both quarterly and monthly dosing for the prophylaxis of migraine in adults [media release]. 1 Apr 2019. http:\/\/www.tevapharm.com."},{"key":"722_CR4","unstructured":"US Food & Drug Administration. FDA approves drug for the preventive treatment of episodic migraine in children ages 6 years and older who weigh 45 kg or more [media release]. 5 Aug 2025. https:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/3eca033."},{"key":"722_CR5","unstructured":"Teva Pharmaceuticals USA Inc. AJOVY\u00ae (fremanezumab-vfrm) injection, for subcutaneous use: US prescribing information. 2025. https:\/\/www.ajovy.com\/globalassets\/ajovy\/ajovy-pi.pdf. Accessed 22 Sep 2025."},{"key":"722_CR6","unstructured":"Labrys Biologics Inc. Labrys Biologics secures $31 Million Series A financing from venture capital firms; acquires phase 2 ready antibody for chronic migraine from Pfizer [media release]. 3 Jan 2013. http:\/\/www.prnewswire.com."},{"key":"722_CR7","unstructured":"Teva Pharmaceutical Industries Ltd. Teva to acquire Labrys Biologics, Inc.: Novel migraine prophylaxis treatment adds significant new dimension to Teva's growing pain care franchise [media release]. 3 Jun 2014. http:\/\/www.tevapharm.com."},{"key":"722_CR8","unstructured":"Teva Pharmaceutical Industries Ltd. Teva completes acquisition of Labrys: opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio [media release]. 21 Jul 2014. http:\/\/www.tevapharm.com."},{"key":"722_CR9","unstructured":"Otsuka Pharmaceutical. Otsuka and Teva sign licensing agreement for Japan on prophylactic migraine drug candidate fremanezumab (TEV-48125) [media release]. 15 May 2017. http:\/\/www.otsuka-us.com."},{"issue":"785","key":"722_CR10","first-page":"1","volume":"13","author":"A Jones","year":"2021","unstructured":"Jones A, Cohen-Barak O, Radivojevic A, et al. Scaling approaches for pediatric dose selection: the fremanezumab (AJOVY\u00ae) journey to select a phase 3 dose using pharmacokinetic data from a phase 1 study. Pharmaceutics. 2021;13(785):1\u201316.","journal-title":"Pharmaceutics"},{"issue":"1","key":"722_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-018-0905-8","volume":"19","author":"L Ohlsson","year":"2018","unstructured":"Ohlsson L, Kronvall E, Stratton J, et al. Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain. 2018;19(1):66.","journal-title":"J Headache Pain"},{"issue":"9","key":"722_CR12","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/cpdd.902","volume":"10","author":"I Cherniakov","year":"2021","unstructured":"Cherniakov I, Cohen-Barak O, Tiver R, et al. A pharmacokinetic bioequivalence study of fremanezumab administered subcutaneously using an autoinjector and a prefilled syringe. Clin Pharmacol Drug Dev. 2021;10(9):1018\u201327.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"722_CR13","first-page":"77","volume":"44","author":"AD Hershey","year":"2024","unstructured":"Hershey AD, Szperka CL, Barash S, et al. Efficacy outcomes from a phase 3, randomised, double-blind, placebo-controlled study of fremanezumab for the preventive treatment of episodic migraine in children and adolescents [abstract no. LB.01]. Cephalalgia. 2024;44(12):77\u20138.","journal-title":"Cephalalgia"},{"issue":"12","key":"722_CR14","first-page":"88","volume":"44","author":"AD Hershey","year":"2024","unstructured":"Hershey AD, Szperka CL, Barash S, et al. Safety outcomes from a phase 3, randomised, double-blind, placebo-controlled study of fremanezumab for the preventive treatment of episodic migraine in children and adolescents [abstract no. LB.P48]. Cephalalgia. 2024;44(12):88\u20139.","journal-title":"Cephalalgia"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00722-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:29:12Z","timestamp":1760714952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00722-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00722-5","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}